Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer.
NICE’s decision, announced today, means that men in England and Wales with prostate cancer will miss out on a highly innovative treatment option. It puts the NHS in England and Wales out of step with Scotland, where olaparib was approved last year for the treatment of prostate cancers with faulty DNA repair genes, like BRCA1 or BRCA2, which have not responded to prior treatment with the hormone therapies enzalutamide or abiraterone acetate.
